Information Provided By: 
Fly News Breaks for April 26, 2019
ILMN
Apr 26, 2019 | 08:14 EDT
Canaccord analyst Mark Massaro lowered his price target for Illumina to $350 from $360 after the company beat on the top and bottom line in Q1 and raised his bottom like 2019 guidance. Massaro tells investors in a research note that he views Q1 as mixed, but reiterates a Buy rating since less than 0.02% of humans have ever been sequenced and clinical sequencing is growing rapidly off an extremely low base.
News For ILMN From the Last 2 Days
There are no results for your query ILMN
